Psychiatric complications of L-dopa treatment of Parkinson's disease at our hospital were less frequent and severe than reported at other institutions. Psychosocial factors were much more prominent in the complications that did occur than a pharmacologic effect of L-dopa. Interest in the connections between L-dopa, catecholamine metabolism and emotional disorder should not lead to neglect of medical-psychological aspects of L-dopa therapy.
Get full access to this article
View all access options for this article.
References
1.
CelesiaGCBarrAN: Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol, Chicago23:193–200, 1970.
2.
JenkinsRBGrohRH: Mental symptoms in Parkinsonian patients treated with L-dopa. Lancet2:177–80, 1970.
3.
SchwabRS: Psychiatric aspects of L-dopa treatment in Parkinson's disease, L-dopa and Parkinsonism. Edited by BarbeauAMcDowellFH. Philadelphia, FA Davis, 1970, pp 325–8.
4.
McDowellFLeeJESwiftT: Treatment of Parkinson's syndrome with L-dihydroxphenylalanine (levodopa). Ann Intern Med72:29–35, 1970.
5.
MuenterMD: Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Neurology, Minneap 20, pt 2, 6–13, 1970.
6.
Goodwin-AustenRBTomlinsonEBFreersCC: Effects of L-dopa in Parkinson's disease. Lancet2:165–8, 1969.
7.
HoehnMDYahrMD: Parkinsonism: Onset, progression and mortality. Neurology, Minneap17:427–42, 1967.
8.
SaxDSFeldmanRDWhiteG: Motorneuron pool activity in Parkinson's syndrome modified by L-dopa therapy (in preparation).
9.
MorseRMLitinEM: Post-operative delirium: A study of etiologic factors. Amer J Psychiat126:388–95, 1969.
10.
BibringE: The mechanism of depression, Affective Disorders. Edited by GreenacreP. New York, International Universities Press, 1953, pp 13–48.
11.
JelliffeSE: What price healing?JAMA94:1393–5, 1930.
12.
HornykiewiczO: Dopamine and brain function. Pharmacol Rev18:925–64, 1966.
13.
NautaWJHMehlerWR: Fibre connections of the basal ganglia, Psychotropic Drugs and Dysfunctions of the Basal Ganglia. Edited by CraneGEGardnerR. Washington, DC, US Government Printing Office (PHS publication 1938), 1969, pp 68–74.
14.
CotziasGCPapavasiliouPSGelleneR: Modification of Parkinsonism: Chronic treatment with L-dopa. New Engl J Med280:337–45, 1969.
15.
PribramKHMelgesFT: Psychophysiological basis of emotion, Handbook of Clinical Neurology (Vol 3). Edited by VinkenPJBruynGW. Amsterdam, North Holland Publishing Co., 1969, pp 316–42.
16.
YahrMD: Psychiatric aspects of L-dopa treatment, L-dopa and Parkinsonism. Edited by BarbeauAMcDowellFH. Philadelphia, FA Davis, 1970, pp 328–9.
17.
LipsittDR: Integration clinic: An approach to the teaching and practice of medical psychology in an out-patient setting, Psychiatry and Medical Practice in a General Hospital. Edited by ZinbergNE. New York, International Universities Press, 1965, pp 231–49.
18.
KennedyJABakstH: The influence of emotions on the outcome of cardiac surgery: A predictive study. Bull NY Acad Med42:811–45, 1966.
19.
BoothG: Psychodynamics in Parkinsonism. Psychosom Med10:1–14, 1948.
20.
FlynnWR: On the psychology of the shaking palsy. Psychiat Quart26:203–22, 1962.
21.
KahanaRJBibringGL: Personality types in medical management, Psychiatry and Medical Practice in a General Hospital. Edited by ZinbergNE. New York, International Universities Press, 1965, pp 108–23.
22.
LipowskiZ: Physical illness, the individual and the coping processes. Psychiat in Med1:91–102, 1970.
23.
SchildkrautJJ: Neuropsychopharmacology and the affective disorders. New Engl J Med281:197–201, 248–255, 302–308, 1969.
24.
ColeJO: The effects of dopa on mood and behavior, L-dopa and Parkinsonism. Edited by BarbeauAMcDowellFH. Philadelphia, FA Davis, 1970, pp 343–7.
25.
SmithATraganzaEHarrisonG: Studies on the effectiveness of antidepressant drugs. Psychopharmacol BullSuppl: 1–53, March 1969.
26.
PearlmanCAGreenbergR: Medical-psychological implications of recent sleep research. Psychiat in Med1:261–76, 1970.
27.
WyattRJFramDHKupferDJ: Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Arch Gen Psychiat24:145–55, 1971.
28.
FramDHMurphyDLGoodwinFK: L-dopa and sleep in depressed patients. Psychophysiology7:317, 1971.
29.
ZarconeVHollisterLDementWC: The effect of L-dopa on the sleep of two depressed patients. Psychophysiology7:314–5, 1971.
30.
KnoppW: Psychiatric changes in patients treated with levodopa. Neurology, Minneap20, pt 2, 23–30, 1970.
31.
GreenbergRPearlmanCA: L-dopa, Parkinsonism and sleep. Psychophysiology7:314, 1971.
32.
WyattRJChaseTNScottJ: Effect of L-dopa on the sleep of man. Nature, London228:999–1001, 1970.
33.
O'BrienCPDiGiacomoJNFahnS: Mental effects of high-dosage levodopa. Arch Gen Psychiat24:61–4, 1970.
34.
PaulMICramerHGoodwinFK: Urinary cyclic A.M.P. in affective illness. Lancet1:996, 1970.
35.
PaulMICramerHBunneyWE: Urinary adenosine 3′, 5′-monophosphate in the switch process from depression to mania. Science171:300–303, 1971.
36.
PaulMIPaukGLDitzionBR: The effect of centrally active drugs on the concentration of brain adenosine 3′, 5′-monophosphate. Pharmacology3:148–54, 1970.
37.
AbdullaYHHamadahK: 3′, 5′ cyclic adenosine monophosphate in depression and mania. Lancet1:378–81, 1970.
38.
PaoP: On manic depressive psychosis: A study of the transition of states. J Amer Psychoanal Ass16:809–32, 1968.
39.
JanowskyDSLeffMEpsteinRS: Playing the manic game. Arch Gen Psychiat22:252–61, 1970.
40.
BunneyWEJrMurphyDLGoodwinFK: The switch process from depression to mania: Relationship to drugs which alter brain amines. Lancet1:1022–1027, 1970.
41.
KetySS: Neurochemical aspects of emotional behavior, Physiological Correlates of Emotion. Edited by BlackP. New York, Academic Press, 1970, pp 61–71.
42.
GoodwinFKMurphyDLBrodieKH: Levodopa: Alterations in behavior. Clin Pharmacol Ther12:383–96, 1971.
